{"id":262,"date":"2021-11-20T11:54:44","date_gmt":"2021-11-20T11:54:44","guid":{"rendered":"http:\/\/localhost:8888\/keith-wordpress\/?post_type=investee&#038;p=262"},"modified":"2021-12-13T09:12:43","modified_gmt":"2021-12-13T09:12:43","slug":"highlight-therapeutics","status":"publish","type":"investee","link":"https:\/\/www.keith.vc\/en\/investee\/highlight-therapeutics\/","title":{"rendered":"Highlight Therapeutics"},"content":{"rendered":"\n<p>Highlight, que antes se conoc\u00eda como Bioncotech Therapeutics S.L, es una empresa privada en fase cl\u00ednica dedicada a liberar todo el potencial de la inmuno-oncolog\u00eda. El f\u00e1rmaco principal es B0-112 y actualmente se est\u00e1 probando en ensayos cl\u00ednicos. Su investigaci\u00f3n se basa en tratamientos basados en oncolog\u00eda.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Highlight, que antes se conoc\u00eda como Bioncotech Therapeutics S.L, es una empresa privada en fase cl\u00ednica dedicada a liberar todo el potencial de la inmuno-oncolog\u00eda. El f\u00e1rmaco principal es B0-112 y actualmente se est\u00e1 probando en ensayos cl\u00ednicos. Su investigaci\u00f3n se basa en tratamientos basados en oncolog\u00eda.<\/p>\n","protected":false},"author":1,"featured_media":438,"comment_status":"open","ping_status":"open","template":"","tags":[],"mkt_place":[32],"porfolio_stage":[4],"angel_fund":[13],"acf":[],"_links":{"self":[{"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/investee\/262"}],"collection":[{"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/investee"}],"about":[{"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/types\/investee"}],"author":[{"embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/comments?post=262"}],"version-history":[{"count":7,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/investee\/262\/revisions"}],"predecessor-version":[{"id":671,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/investee\/262\/revisions\/671"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/media\/438"}],"wp:attachment":[{"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/media?parent=262"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/tags?post=262"},{"taxonomy":"mkt_place","embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/mkt_place?post=262"},{"taxonomy":"porfolio_stage","embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/porfolio_stage?post=262"},{"taxonomy":"angel_fund","embeddable":true,"href":"https:\/\/www.keith.vc\/en\/wp-json\/wp\/v2\/angel_fund?post=262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}